Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 12/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11308791 | 0.84 | KMT2A (0.54) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL755296 | 0.83 | SMN1; SMN2 (0.52) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL1092177 | 0.82 | KMT2A (0.53) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL5245757 | 0.81 | L3MBTL1 (0.57) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL25620248 | 0.79 | MEN1 (0.71) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL21397874 | 0.79 | LMNA (0.58) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL1092605 | 0.78 | MAOB (0.59) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL9986996 | 0.78 | MAPT (0.51) | KMT2AMEN1ALDH1A1RAB9AMAPK1 | |
| SCHEMBL29589944 | 0.77 | CES2 (0.74) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL3393599 | 0.77 | MAPT (0.59) | KMT2AMAOBALDH1A1RAB9AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011528012-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2328882-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK Pharmaceuticals d.d. (SI) | 2011-06-08 | — | — | EP | claimed |
| WO-2010007022-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | WO | claimed |
| CN-113402490-A | Preparation method of 1,2,6, 7-tetrahydro-8H-indeno [5,4-b ] furan-8-one | 白银京宇新药业有限公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2328882-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK Pharmaceuticals d.d. (SI) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010092107-A1 | SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE | LEK PHARMACEUTICALS D.D. (SI) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010007022-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007022-A1 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5,4-B]FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | WO | disclosed |
| EP-1478671-B1 | UV-CROSSLINKABLE COPOLYMERS | BASF AG (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-7091296-B2 | UV-crosslinkable copolymers | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-15 | — | — | US | disclosed |
| US-20050080213-A1 | copolymerizable photoinitiators comprising ortho-, meta-, or para-vinyl ethers of acetophenone or benzophenone; addition copolymerization in solution; binders and pressure sensitive adhesives; high cohesion and adhesion; chemical resistance to hydrolysis; storage stability | BASF AKTIENGESELLSHAFT (DE) | 2005-04-14 | — | — | US | disclosed |
| EP-1478671-A1 | UV-CROSSLINKABLE COPOLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003070792-A1 | UV- CROSSLINKABLE COPOLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | KMT2A 3298/4885MEN1 2138/4885MAOB 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.